NCT03466814已完成不适用
ORENCIA Safety Surveillance in Japanese Children and Adolescents With Active Juvenile Idiopathic Arthritis (JIA)
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 82 人开始时间: 2018年4月6日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 82
- 试验地点
- 1
- 主要终点
- Number of adverse events
研究概览
简要总结
Observational study of abatacept in the treatment of JIA in Japan.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All JIA participants who initiate treatment with Orencia in accordance with the prescribing information
排除标准
- •Participants receiving Orencia for an off-label indication
- •Other protocol defined inclusion/exclusion criteria could apply
结局指标
主要结局
Number of adverse events
时间窗: 1 year
次要结局
- Safety measured by number of participants who receive at least 1 dose of Orencia(1 year)
- Efficacy measured by number of participants who receive at least 1 dose of Orencia(1 Year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid ArthritisRheumatoid ArthritisNCT00484289Bristol-Myers Squibb217
进行中（未招募）
不适用
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic ArthritisJuvenile Idiopathic ArthritisNCT01357668Bristol-Myers Squibb800
已完成
3 期
A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial SeizuresEpilepsies, PartialNCT00620555Pfizer's Upjohn has merged with Mylan to form Viatris Inc.65
招募中
不适用
A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin LymphomaHodgkin LymphomaNCT05481437Takeda8
已完成
不适用
Paediatric Subjects - Special SurveyDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT01538576Novo Nordisk A/S71